Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Checkmate Pharmaceuticals Inc is a biotechnology business based in the US. Checkmate Pharmaceuticals shares (CMPI) are listed on the NASDAQ and all prices are listed in US Dollars. Checkmate Pharmaceuticals employs 28 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Active traders
Our top pick for
Beginners
Our top pick for
Building a portfolio
| Latest market close | $2.54 |
|---|---|
| 52-week range | $2.52 - $17.85 |
| 50-day moving average | $3.50 |
| 200-day moving average | $5.36 |
| Wall St. target price | $18.33 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.73 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.535 from 2022-01-14
| 1 week (2022-01-10) | -5.41% |
|---|---|
| 1 month (2021-12-16) | -18.75% |
| 3 months (2021-10-15) | -38.17% |
| 6 months (2021-07-16) | -50.68% |
| 1 year (2021-01-15) | -80.85% |
|---|---|
| 2 years (2020-01-13) | N/A |
| 3 years (2019-01-13) | N/A |
| 5 years (2017-01-13) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -31.65% |
| Return on equity TTM | -54.44% |
| Profit margin | 0% |
| Book value | $3.77 |
| Market capitalisation | $55.8 million |
TTM: trailing 12 months
We're not expecting Checkmate Pharmaceuticals to pay a dividend over the next 12 months.
Checkmate Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.